May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Sjogren's Syndrome, Current Prescribing Trends in Britain
Author Affiliations & Notes
  • A.J. Mollan
    Medicine, Health Policy & Practice, University of East Anglia, Norwich, United Kingdom
  • S.P. Mollan
    Ophthalmology, Birmingham Midland Eye Centre, Birmingham, United Kingdom
  • R.D. Bhojwani
    Ophthalmology, Birmingham Midland Eye Centre, Birmingham, United Kingdom
  • B.A. Noble
    Ophthalmology, University of Leeds, Leeds, United Kingdom
  • Footnotes
    Commercial Relationships  A.J. Mollan, None; S.P. Mollan, None; R.D. Bhojwani, None; B.A. Noble, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5024. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.J. Mollan, S.P. Mollan, R.D. Bhojwani, B.A. Noble; Sjogren's Syndrome, Current Prescribing Trends in Britain . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5024.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To analyse who diagnoses Sjogren’s Syndrome (SS); treatments used, the level of comfort gained and frequency of application required, and preparations which have been discontinued. Methods: A retrospective non–interventional observational survey of the British Sjogren’s Syndrome Association (BSSA). 2200 members were sent a questionnaire. Subjects recorded their current medications (steroids, disease modifying anti–rheumatoid drugs (DMARDs) and artificial tear substitutes) and what topical treatments were beneficial. 1087 respondents took part, a 49.4% response rate (6.7% males, 93.3% females) with age range of 17–91years. Results: The diagnosing practitioner was a cross–specialty mix including dentists and cardiologists. 30.4% considered themselves to have Primary SS, 68.3% Secondary SS and 1.3% unknown. 8.5% of secondary SS took prednisolone, 16.6% DMARDs or 9.3% took both. The most common DMARD was hydroxychloroquine (112/123). 24 individuals took oral pilocarpine. 4.8% (53/1087) of this cohort did not use any topical preparations. Of 1034 that used topicals, 51.8% (531/1034) used a single preparation: Hypromellose being the most common (45.6%), Viscotears 18.8%, Liquifilm 8.7%, Lacrilube 3.2%. 51.4% had discontinued one or more topicals due to inadequate benefit. Conclusions: A front–line subjective view of the preferred preparations in SS is presented: showing that only a relatively select number of medications are used regularly. Exploring the subjective benefits and drawbacks of different tear substitutes can help improve patient comfort. As dry eye prescribing is on a hierarchal approach it is not surprising that 51.4% of the cohort discontinued one or more topical agent.

Keywords: autoimmune disease • autoimmune disease • autoimmune disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.